Ana Frank GarcÃ-a

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9028600/publications.pdf

Version: 2024-02-01

69 papers 11,917 citations

36 h-index 76900 74 g-index

74 all docs

74 docs citations

times ranked

74

15860 citing authors

#	Article	IF	Citations
1	A Blood-Based, 7-Metabolite Signature for the Early Diagnosis of Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 45, 1157-1173.	2.6	91
2	Spanish Multicenter Normative Studies (NEURONORMA Project): Normative Data and Equivalence of Four BNT Short-Form Versions. Archives of Clinical Neuropsychology, 2014, 29, 60-74.	0.5	13
3	The Partial Volume Effect in the Quantification of 1H Magnetic Resonance Spectroscopy in Alzheimer's Disease and Aging. Journal of Alzheimer's Disease, 2014, 42, 801-811.	2.6	8
4	Diagnostic Validity of the Alzheimer's Disease Functional Assessment and Change Scale in Mild Cognitive Impairment and Mild to Moderate Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2014, 37, 366-375.	1.5	8
5	Assessing the role of the TREM2 p.R47H variant as a risk factor for Alzheimer's disease and frontotemporal dementia. Neurobiology of Aging, 2014, 35, 444.e1-444.e4.	3.1	92
6	Cognitive and Neuroimaging Profiles in Mild Cognitive Impairment and Alzheimer's Disease: Data from the Spanish Multicenter Normative Studies (NEURONORMA Project). Journal of Alzheimer's Disease, 2014, 41, 887-901.	2.6	28
7	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. PLoS ONE, 2014, 9, e94661.	2.5	155
8	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 2013, 45, 1452-1458.	21.4	3,741
9	Rare Variants in Calcium Homeostasis Modulator 1 (CALHM1) Found in Early Onset Alzheimer's Disease Patients Alter Calcium Homeostasis. PLoS ONE, 2013, 8, e74203.	2.5	26
10	The Effects of Different Attentional Demands in the Identification of Emotional Facial Expressions in Alzheimer's Disease. American Journal of Alzheimer's Disease and Other Dementias, 2012, 27, 530-536.	1.9	21
11	Genetic variability of the gene cluster CALHM1–3 in sporadic Creutzfeldt-Jakob disease. Prion, 2012, 6, 407-412.	1.8	14
12	Using artificial neural networks in clinical neuropsychology: High performance in mild cognitive impairment and Alzheimer's disease. Journal of Clinical and Experimental Neuropsychology, 2012, 34, 195-208.	1.3	39
13	A Common BACE1 Polymorphism Is a Risk Factor for Sporadic Creutzfeldt-Jakob Disease. PLoS ONE, 2012, 7, e43926.	2.5	10
14	Genetic variations in tau-tubulin kinase-1 are linked to Alzheimer's disease in a Spanish case-control cohort. Neurobiology of Aging, 2011, 32, 550.e5-550.e9.	3.1	23
15	IGF-I gene variability is associated with an increased risk for AD. Neurobiology of Aging, 2011, 32, 556.e3-556.e11.	3.1	36
16	Evidence of the association of BIN1 and PICALM with the AD risk in contrasting European populations. Neurobiology of Aging, 2011, 32, 756.e11-756.e15.	3.1	82
17	Genetic variation in APOE cluster region and Alzheimer's disease risk. Neurobiology of Aging, 2011, 32, 2107.e7-2107.e17.	3.1	59
18	PLA2G3, a Gene Involved in Oxidative Stress Induced Death, is Associated with Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 22, 1181-1187.	2.6	25

#	Article	lF	CITATIONS
19	Genetic Cross-Interaction between APOE and PRNP in Sporadic Alzheimer's and Creutzfeldt-Jakob Diseases. PLoS ONE, 2011, 6, e22090.	2.5	43
20	Genetic Variation in the Tau Kinases Pathway May Modify the Risk and Age at Onset of Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 27, 291-297.	2.6	21
21	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genetics, 2011, 43, 429-435.	21.4	1,708
22	APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Molecular Psychiatry, 2011, 16, 903-907.	7.9	529
23	La formación en neurofisiologÃa en el programa educativo de la especialidad de neurologÃa en España. NeurologÃa, 2011, 26, 272-278.	0.7	2
24	Spanish Multicenter Normative Studies (Neuronorma Project): Norms for the Abbreviated Barcelona Test. Archives of Clinical Neuropsychology, 2011, 26, 144-157.	0.5	36
25	Clinical progression of moderate-to-severe Alzheimer's disease and caregiver burden: a 12-month multicenter prospective observational study. International Psychogeriatrics, 2010, 22, 1265-1279.	1.0	41
26	Prospective One-Year Cost-of-Illness Study in a Cohort of Patients with Dementia of Alzheimer's Disease Type in Spain: The ECO Study. Journal of Alzheimer's Disease, 2010, 19, 601-615.	2.6	65
27	The CALHM1 P86L Polymorphism is a Genetic Modifier of Age at Onset in Alzheimer's Disease: a Meta-Analysis Study. Journal of Alzheimer's Disease, 2010, 22, 247-255.	2.6	54
28	A megalin polymorphism associated with promoter activity and Alzheimer's disease risk. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 895-902.	1.7	24
29	Caspase-1 genetic variation is not associated with Alzheimer's disease risk. BMC Medical Genetics, 2010, 11, 32.	2.1	8
30	Epistasis Between Intracellular Cholesterol Trafficking-Related Genes (NPC1 and ABCA1) and Alzheimer's Disease Risk. Journal of Alzheimer's Disease, 2010, 21, 619-625.	2.6	21
31	Citicoline, use in cognitive decline: Vascular and degenerative. Journal of the Neurological Sciences, 2010, 299, 188-192.	0.6	51
32	Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP. Neurobiology of Aging, 2010, 31, 725-731.	3.1	196
33	Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders. Current Alzheimer Research, 2009, 6, 144-151.	1.4	236
34	Spanish Multicenter Normative Studies (NEURONORMA Project): Methods and Sample Characteristics. Archives of Clinical Neuropsychology, 2009, 24, 307-319.	0.5	206
35	Spanish Multicenter Normative Studies (NEURONORMA Project): Norms for the Visual Object and Space Perception Battery-Abbreviated, and Judgment of Line Orientation. Archives of Clinical Neuropsychology, 2009, 24, 355-370.	0.5	32
36	Spanish Multicenter Normative Studies (NEURONORMA Project): Norms for Verbal Fluency Tests. Archives of Clinical Neuropsychology, 2009, 24, 395-411.	0.5	201

#	Article	IF	CITATIONS
37	DYRK1A genetic variants are not linked to Alzheimer's disease in a Spanish case-control cohort. BMC Medical Genetics, 2009, 10, 129.	2.1	11
38	Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nature Genetics, 2009, 41, 1094-1099.	21.4	2,155
39	Post-stroke depression: can we predict its development from the acute stroke phase?. Acta Neurologica Scandinavica, 2009, 120, 150-156.	2.1	32
40	A free radicalâ€generating system induces the cholesterol biosynthesis pathway: a role in Alzheimer's disease. Aging Cell, 2009, 8, 128-139.	6.7	36
41	Spanish Multicenter Normative Studies (NEURONORMA Project): Norms for the Stroop Color-Word Interference Test and the Tower of London-Drexel. Archives of Clinical Neuropsychology, 2009, 24, 413-429.	0.5	7 5
42	Spanish Multicenter Normative Studies (NEURONORMA Project): Norms for Verbal Span, Visuospatial Span, Letter and Number Sequencing, Trail Making Test, and Symbol Digit Modalities Test. Archives of Clinical Neuropsychology, 2009, 24, 321-341.	0.5	149
43	The role of interference in identification of emotional facial expressions in normal ageing and dementia. European Journal of Cognitive Psychology, 2009, 21, 428-444.	1.3	16
44	Spanish Multicenter Normative Studies (NEURONORMA Project): Norms for the Rey-Osterrieth Complex Figure (Copy and Memory), and Free and Cued Selective Reminding Test. Archives of Clinical Neuropsychology, 2009, 24, 371-393.	0.5	133
45	Spanish Multicenter Normative Studies (NEURONORMA Project): Norms for Boston Naming Test and Token Test. Archives of Clinical Neuropsychology, 2009, 24, 343-354.	0.5	74
46	Presenilin 1 Polymorphism Associated with Alzheimer's Disease in Apolipoprotein E4Carriers. Dementia and Geriatric Cognitive Disorders, 2008, 26, 440-444.	1.5	10
47	Double stranded RNA activated EIF2 α kinase (EIF2AK2; PKR) is associated with Alzheimer's disease. Neurobiology of Aging, 2008, 29, 1160-1166.	3.1	43
48	Plasma Aminothiol Compounds, but Not Serum Tumor Necrosis Factor Receptor II and Soluble Receptor for Advanced Glycation End Products, Are Related to the Cognitive Impairment in Alzheimer's Disease and Mild Cognitive Impairment Patients. NeuroImmunoModulation, 2007, 14, 163-167.	1.8	35
49	Poststroke Depression: Importance of Its Detection and Treatment. Cerebrovascular Diseases, 2007, 24, 181-188.	1.7	48
50	A TAP2 genotype associated with Alzheimer's disease in APOE4 carriers. Neurobiology of Aging, 2007, 28, 519-523.	3.1	29
51	Association of DSC1, a gene modulated by adrenergic stimulation, with Alzheimer's disease. Neuroscience Letters, 2006, 408, 203-208.	2.1	9
52	Diagnostic accuracy of the Eurotest for dementia: a naturalistic, multicenter phase II study. BMC Neurology, 2006, 6, 15.	1.8	43
53	Consistency of the Benefits of Stroke Units over Years of Operation: An 8-Year Effectiveness Analysis. Cerebrovascular Diseases, 2006, 21, 173-179.	1.7	40
54	Evaluation of Maximal Respiratory Pressures in Myasthenia gravis. European Neurology, 2004, 52, 136-140.	1.4	3

#	Article	IF	CITATIONS
55	Polymorphism in genes involved in adrenergic signaling associated with Alzheimer's. Neurobiology of Aging, 2004, 25, 853-859.	3.1	39
56	APOE genotype in cerebrovascular disease and vascular dementia. Journal of the Neurological Sciences, 2002, 203-204, 173-176.	0.6	24
57	Increased cerebrospinal fluid Fas (Apo-1) levels in Alzheimer's disease. Brain Research, 2000, 869, 216-219.	2.2	82
58	A polymorphism in the tau gene associated with risk for Alzheimer's disease. Neuroscience Letters, 2000, 278, 49-52.	2.1	66
59	Alzheimer's risk associated with human apolipoprotein E, alpha-2 macroglobulin and lipoprotein receptor related protein polymorphisms: absence of genetic interactions, and modulation by gender. Neuroscience Letters, 2000, 289, 213-216.	2.1	39
60	Increased cerebrospinal fluid cAMP levels in Alzheimer's disease. Brain Research, 1999, 846, 265-267.	2.2	66
61	A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia. Nature Genetics, 1998, 18, 69-71.	21.4	291
62	Missense mutation E318G of the presenilin-1 gene appears to be a nonpathogenic polymorphism. Annals of Neurology, 1998, 44, 985-986.	5. 3	30
63	Encephalopathy and biopsy-proven cerebrovascular inflammatory changes in a cocaine abuser. European Journal of Neurology, 1998, 5, 103-107.	3.3	34
64	Syndrome of Headache With Neurological Deficits and CSF Lymphocytosis: A Spreading Depression Mechanism? The Role of SPECT. Headache, 1998, 38, 324-324.	3.9	15
65	Risk for Alzheimer's disease correlates with transcriptional activity of the APOE gene. Human Molecular Genetics, 1998, 7, 1887-1892.	2.9	135
66	Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type Journal of Neurology, Neurosurgery and Psychiatry, 1995, 59, 280-283.	1.9	81
67	Amino acid concentrations in cerebrospinal fluid and serum in Alzheimer's disease and vascular dementia. Journal of Neural Transmission Parkinson's Disease and Dementia Section, 1993, 6, 1-9.	1.2	60
68	Relationship of interleukin- $1\hat{l}^2$ and \hat{l}^2 2-microglobulin with neuropeptides in cerebrospinal fluid of patients with dementia of the Alzheimer type. Journal of Neuroimmunology, 1993, 48, 235-240.	2.3	35
69	Absence Status following Metrizamide Myelography: Management of Nonresponders. European Neurology, 1988, 28, 341-344.	1.4	4